# NX-1607 in advanced malignancies

Source: https://onco.cc/trials/nct05107674/  
OnCo record `nct05107674` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This early study tests NX-1607 alone or with paclitaxel in selected advanced cancers. It seeks a tolerable dose and early evidence of treatment activity.

## Summary

This early study tests NX-1607 alone or with paclitaxel in selected advanced cancers. It seeks a tolerable dose and early evidence of treatment activity.

Interventional study registered as NCT05107674, sponsored by Nurix Therapeutics, Inc.. Registry phase: 1. Registry enrollment is 345 participants (estimated). Registry status checked October 10, 2026: recruiting. UCSF lists this study as open to eligible people; local availability and overall registry status are separate. See the registry for full eligibility and current sites.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-10
- Also known as: A Study of NX-1607 in Adults With Advanced Malignancies
- Tags: ucsf-breast-coverage; interventional
- Registry id: NCT05107674
- Phase: 1
- Setting: Selected advanced cancers, including triple-negative breast cancer
- Sponsor: Nurix Therapeutics, Inc.

## Sources

- ClinicalTrials.gov NCT05107674: https://clinicaltrials.gov/study/NCT05107674
- UCSF study listing and local availability: https://clinicaltrials.ucsf.edu/trial/NCT05107674

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- institutions: [UCSF Helen Diller Family Comprehensive Cancer Center](https://onco.cc/institutions/ucsf/)

---
JSON: https://onco.cc/api/v1/entities/nct05107674.json